COMMUNIQUÉS West-GlobeNewswire

-
Cybrexa Therapeutics Receives SBIR Grant to Support Development of Lead Candidate CBX-11 in Combination with Chemotherapy Agents
02/07/2019 -
Grace Colón succeeds Amy Abernethy on the CareDx Board
02/07/2019 -
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib
02/07/2019 -
Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer
02/07/2019 -
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
02/07/2019 -
Quotient Board Announces Contract Extension of CEO Franz Walt
02/07/2019 -
Blueberries Executes Definitive Agreement to Acquire Cannabis Cultivation, Processing & Manufacturing Rights for 3.2M Square Foot Property in Argentina
02/07/2019 -
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
02/07/2019 -
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
02/07/2019 -
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
02/07/2019 -
TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology
02/07/2019 -
Helius Medical Technologies to Release Second Quarter of Fiscal Year 2019 Financial Results on August 8, 2019
02/07/2019 -
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
02/07/2019 -
ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
02/07/2019 -
Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada
02/07/2019 -
Pluristem Therapeutics’ CEO Issues Shareholder Letter
02/07/2019 -
Aleafia Health Secures Health Canada Permits to Export Cannabis Products to Australia
02/07/2019 -
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus
02/07/2019 -
SV Health Investors announces the appointment of Jonathan Behr, PhD as Partner in the Dementia Discovery Fund
02/07/2019
Pages